Calypte und die Zeit nach AIDS2004 in Bangkok
Time Price Volume Exchange Info
Was ich nicht verstehe sind die Blöcke die nicht ausgeführt worden sind um 1 Minute!
16:26:33 0.650 2500 OTC BBS
16:26:32 0.660 2500 OTC BBS
16:05:25 0.658 80000 OTC BBS
16:01:13 0.695 290600 OTC BBS
15:57:30 0.615 2500 OTC BBS
15:57:29 0.620 2500 OTC BBS
15:57:25 0.620 12500 OTC BBS
15:57:24 0.615 12500 OTC BBS
15:56:58 0.615 1000 OTC BBS at Bid
15:56:04 0.615 6000 OTC BBS
Wann beginnt Konferenz Uhrzeitmäßig?
Danke Lucky
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
http://www.patent.gov.uk/tm/tmj/journals/6532/jnl.pdf (Seite 40 !)
Calypte Biomedical Corp. (ticker: CYPT.OB, exchange: Other OTC) News Release - 14-Apr-2004
--------------------------------------------------
Calypte Announces Execution of a Research and Development Agreement With CDC for Rapid HIV Incidence Test
ALAMEDA, Calif., April 14 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), a company engaged in developing rapid tests for HIV diagnosis and the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot supplemental test, announced today that it has executed a CRADA -- a Cooperative Research and Development Agreement -- with the Centers for Disease Control and Prevention (CDC) for the development of a unique new HIV rapid blood assay. Like current rapid test assays, the proposed device will be for diagnostic use to detect HIV antibodies, but it will also be for use in population studies to estimate the proportion of HIV-1 infections that have occurred in the last six months. This assay will use a proprietary recombinant protein that will include the amino acid sequences identified from the immunodominant regions of the transmembrane glycoprotein (gp41) identified from multiple subtypes of HIV-1 group M.
The CRADA between Calypte and the CDC provides for the development of a test to estimate the incident HIV infections (of less than 6 months duration) in a population survey. The purpose of the test is to provide a simplified and rapid format that can be performed in resource poor settings and remote outreach locations as a public health surveillance tool. The test should be particularly suitable for settings with limitations in blood collection capacity, laboratory facilities, or specimen transport. The test will be designed to provide invaluable information to Public Health agencies concerning the course of the HIV pandemic, such as identifying populations where new infections are occurring most frequently, allowing agencies to measure the effectiveness of prevention efforts in specific risk groups, and identifying high-incidence cohorts for prevention trials (e.g. microbicide, vaccine etc).
Calypte recently announced that it had obtained a non-exclusive license from the CDC to manufacture a serum enzyme Immunoassay test that can measure the proportion of infections that are recently acquired (less than 6 months) for use in estimating HIV incidence. This assay is a laboratory based technology that is performed on samples from individuals previously tested and found to be positive for HIV antibodies. Such a test could have applications in helping public health officials to determine which populations have the highest rate of new infections, and by extension, where they need to focus their intervention efforts.
Dr. Richard George, President and CEO of Calypte commented that "A simplified and rapid format for serologic assays to estimate HIV incidence is a logical progression and refinement of the currently used, laboratory based EIA. The ability to perform tests for recent infection for public health surveillance purposes in all types of environments will dramatically expand the use and reduce the cost of incidence testing used to monitor the effectiveness of HIV prevention programs."
Tony Cataldo, Executive Chairman of Calypte, stated, "Calypte is pleased to have completed this second agreement with the CDC and to provide science that will allow Public Health agencies to focus their resources on HIV and AIDS prevention measures that can be shown by empirical data to be effective."
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
siehe: http://www.patent.gov.uk/tm/tmj/journals/6520/jnl.pdf (Seiten 113 u. 114)
Nun war aber die Publication (Veröffentlichung) für das gestern 09.07.04 erscheinende Trademark-Journal angekündigt.
siehe:
Publication in Trade Marks Journal
Journal Page Publication Date
First Advert 6520 27.02.2004
Registration 6538 09.07.2004
http://www.patent.gov.uk/tm/tmj/journals/6520/domestic/2352402.html
Im diesem gestrigen Journal erschien "Calypte Rapid" aber nicht ! Ich geh davon aus, dass sich einige Investoren (vor allem größere, die von solchen Journals überhaupt wissen) etwas in die Hose machen und Schiss bekommen haben, dass da was nicht ganz glatt läuft (das Vertrauen in Caly ist halt immer noch nicht wieder so ganz hergestellt). Noch dazu hätte das Datum ja bestens gepasst (Veröffentlichung zwei Tage vor Bangkok und dann in Bangkok das neue Produkt vorstellen).
Deshalb haben einige erstmal sicherheitshalber Ihre Anteile verkauft. Ich denke, dass es mit dem Kurs bald wieder raufgeht, sobald Caly evtl. schon im nächsten Journal entsprechend erscheint oder News z.B. über in Bangkok geschlossene Aufträge veröffentlicht werden.
Mal sehen was weiter passiert. Ich hoffe das Ganze hat Euch interessiert- auch wenn es etwas kompliziert erscheint.
Hatt mich ne Menge Zeit gekostet ;-)
Was meint Ihr dazu ?
Grüße
Kade_I
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
meint ihr nicht das die news ab Montag kommen ?
zwei Stellig wären doch dann drin oder : )
Dennke News werden kommen aber gleich so das der Kurs durch die Decke geht????????
Wäre mir Recht den dann wäre ich EUROMILLIONÄR und dann bräuchte ich nicht mehr zu arbeiten grins
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
Calypte Developing HIV-1/2 Oral Fluid Rapid Tests
Tuesday May 25, 8:55 am ET
Launch Expected During Second Half Of 2004
ALAMEDA, Calif., May 25 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT - News), a developer, manufacturer and marketer of HIV diagnostic tests, today announced that it has developed a rapid test for HIV-1/2 that can be performed on an oral fluid sample. HIV results are available from the new Calypte Oral Fluid Test within 20 minutes. In-house evaluation of the rapid oral fluid assays against commercial serum panels spiked into oral fluid at a dilution that simulates actual oral fluid samples has shown to be highly accurate with sensitivity comparable to most laboratory based enzyme immunoassays. Specificity based on over 500 combined samples from several sources was shown to be 99.8%. In addition, the Calypte rapid oral fluid assay has been in an independent clinical study at the Anonymous Clinic in Bangkok, Thailand for more than a month and results are encouraging.
Dr. Richard George, President and CEO of Calypte stated that "HIV Vanguard (TM) OMT" provides the final piece to the Calypte menu of tests that offers the HIV testing community the opportunity to choose from a complete line of rapid tests that can be used to test urine, oral fluid, whole blood, and serum/plasma. Our blood rapid test is fully validated and transfer of this technology to our manufacturing partner is underway. Urine and oral fluid are in the final phases of field testing and if testing continues at the current level of performance, we expect that these tests will be ready for market in the second half of 2004."
Calypte has previously announced plans to manufacture its rapid tests in China and Thailand. The Thailand facility is expected to be in production by August of 2004. China is expected to follow later in the 4th quarter of 2004.
According to Dr. George, "The projected addition of the rapid tests will supplement our existing product lines that currently include FDA-approved urine EIA, urine Western blot and serum Western blot tests, as well as a novel HIV-1 incidence EIA test. Calypte provides one of the most complete lines of HIV EIA tests available from any single company."
Current HIV/AIDS Testing:
A May 2004 report by the Global Business Coalition on HIV/AIDS (GBC), based on their own estimates and that of the World Health Organization (WHO), disclosed that less than 10% of infected individuals in the developing world know their HIV status. According to the report, new infections are on the rise -- and only 400,000 of the 6 million people in need of antiretroviral therapy have access to these life saving medicines. Testing for HIV serves as an entry point for both prevention and treatment. The objective of treating 3,000,000 people by the end of 2005, the stated goal of the WHO "3 by 5" Initiative, would require that 500,000 people will need to be tested each day. This is based on the report's estimate that 50,000 people will test positive in hard hit countries where the prevalence rates average 10%, and that 10% or 5,000 per day of those will require immediate initiation of treatment. GBC states that the challenge is enormous but attainable with increases in funding from donor governments, reductions in drug and diagnostic pricing, integration of public-private delivery of healthcare and overarching shifts in policy.
Calypte will be part of a working group with the GBC at the July 2004 XV International AIDS Conference in Bangkok Thailand.
About Calypte Biomedical:
Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of in vitro diagnostic tests, primarily for the detection of antibodies to Human Immunodeficiency Virus (HIV), and other sexually transmitted and infectious diseases. Calypte's currently marketed laboratory-based tests include an enzyme immunoassay (EIA) HIV-1 antibody screening test and an HIV-1 antibody western blot supplemental test, the only two FDA-approved HIV-1 antibody tests for use on urine samples, as well as an FDA-approved serum HIV- 1 antibody western blot supplemental test. Calypte is actively engaged in developing new test products for the rapid detection of HIV and other infectious diseases. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other infectious diseases may make important contributions to public health.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2003 and its subsequent filings with the SEC.
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
HIV Oral Test To Be Available Shortly
05.31.04
(Los Angeles, California) A new HIV test that uses an oral swab could be on the market later this year its manufacturer says. Calypte Biomedical says the test can be performed on an oral sample or from urine and results would be known in about 20 minutes.
The Calypte Oral Fluid Test is currently undergoing trials in Thailand. The company says the test has an accuracy rate of 99.8 % about the same as blood tests for HIV.
"Urine and oral fluid are in the final phases of field testing and if testing continues at the current level of performance, we expect that these tests will be ready for market in the second half of 2004," said Dr. Richard George, President and CEO of Calypte.
George said the ease of using the test may encourage people who have resisted to be tested for HIV.
A May 2004 report by the Global Business Coalition on HIV/AIDS, based on their own estimates and that of the World Health Organization, showed that less than 10% of infected individuals in the developing world know their HIV status.
According to the report, new infections are on the rise -- and only 400,000 of the 6 million people in need of antiretroviral therapy have access to these life saving medicines.
Testing for HIV serves as an entry point for both prevention and treatment. The objective of treating 3,000,000 people by the end of 2005, the stated goal of the WHO "3 by 5" Initiative, would require that 500,000 people will need to be tested each day.
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
http://www.nappsi.org/rolodex.php?id=11
Mir ist nicht wirklich langweilig, falls das jemand denkt ;-)
Dachte mir ich erforsche heute mal wieder das Netz nach Calypte und geb die gefundenen Infos an Euch weiter !
Grüße
Kade_I
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
SIMPLE HIV TEST COMING
A new HIV test using a mouth swab, currently undergoing trials in Thailand, may appear on the market later this year. Dr. Richard George, CEO of Calypte Biomedical says the test can be made on an oral sample, or from urine, and results would be available in about 20 minutes. He said the test is 99.8% accurate, about the same as HIV blood tests. "Urine and oral fluid are in the final phases of field testing and, if testing continues at the current level of performance, we expect that these tests will be ready for marketing in the second half of 2004," he said, adding that the ease of the test may encourage people who have resisted HIV tests to use this system. Earlier this month, the Global Business Coalition on HIV/AIDS, based on their own estimates and that of the World Health Organization, reported that less than 10% of those infected in the developing world know of their HIV status. According to the GBC report, new infections are on the rise, and only 400,000 of the 6 million people in need of antiretroviral therapy have access to life saving medicines.
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
aber solange nichts direkt von Caly kommt oder bestätigt wird,
kannste das in der Pfeife rauchen.
Machst es Dir etwas einfach mit dieser Aussage !
Außerdem was solls, meine Frau ist krank und ich hock heute halt mal lange vorm PC. Scheißegal, bringt auch mal Spaß.
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
Ich wollte nur sagen,jede Menge Sachen über Caly in verschiedenen Links,
aber von denen selbst kommt im Moment zu wenig.
Frage:Was wird denn beklagt?
Gute Genesungswünsche an deine Frau!!!
U-N and other experts call for routine H-I-V testing in the developing world
By Associated Press
Saturday, July 10, 2004
Bangkok, Thailand - U-N health experts are calling for routine AIDS testing in the developing world, instead of leaving it to people to request an H-I-V test.
Experts say 90 percent of those infected with the AIDS virus have no idea they are carrying it. So the U-N AIDS agency and the World Health Organization now advocate routine testing in countries where H-I-V is widespread and treatment is available.
The change in recommended policy was announced ahead of the opening tomorrow of the International AIDS Conference in Bangkok.
The chief of U-N-AIDS says there are ``millions of missed opportunities'' to diagnose AIDS early or to discuss prevention.
Experts say there would be safeguards against discrimination. Many people have avoided H-I-V tests because they fear the stigma if people know they are infected.
gruß werweiß
BY CAROL ANN CAMPBELL
Star-Ledger Staff
Tyran Wilcher gave a pinprick of blood to the medical technician and waited the longest 20 minutes of his life.
"It's scary," the 43-year-old Newark man said of the new rapid HIV procedure that is changing AIDS testing around the nation.
Advertisement
Wilcher waited for his results one recent afternoon at the office of the North Jersey Community Research Initiative, a Newark group that promotes HIV testing. During this time, a counselor interviewed him about his risk factors. Wilcher said he had engaged in unprotected sex. Soon there was a knock on the door and Wilcher got his results: Negative.
He took the good news as an opportunity to change his life. "I am not going to be out there anymore," he said. "Just one partner."
HIV testing and follow-up counseling, a process that once took as long as two weeks, is being compressed into one short session through a new generation of HIV tests.
These rapid tests provide results in 20 minutes and have been used since January by New Jersey AIDS organizations, health departments and hospitals. Experts said the new tests make it easier to find out who is HIV positive so people can enter counseling and treatment, prolonging their lives and reducing chances they will spread the virus.
"It's changing the whole horizon in New Jersey and the way we do testing. People get on-the-spot counseling," said Carolyn Holmes, deputy commissioner for public health services for the state Department of Health and Senior Services.
The new tests overcome a major obstacle of previous procedures: getting test results to the people who took them. Holmes said about 45 percent of people who took the standard test in New Jersey never returned for their results.
"If people were positive and took a confidential test, we had no way of even reaching them," Holmes said. "They would still be out there spreading the disease. Now, people can get on-the-spot counseling."
More than 61,000 people in New Jersey have been diagnosed with HIV or AIDS since the beginning of the epidemic two decades ago. About 31,000 people in the state now live with AIDS or HIV. But many others have the disease and do not know it. The U.S. Centers for Disease Control and Prevention estimates 1 million Americans are HIV positive, but 250,000 of them do not know they have been infected.
The aim of testing is to find these people.
State health officials have been training technicians on how to administer the new test. During a recent pilot program at the Robert Wood Johnson University Hospital in New Brunswick, 2,000 patients took the rapid test. Eighty were HIV positive and all but one received immediate counseling.
In counseling, people receive information about condoms, drug treatment (if necessary) and other measures to stop the spread of the disease.
The test widely in use now is the OraQuick Rapid HIV-1 Antibody Test by OraSure Technologies Inc., of Bethlehem, Pa. New tests are on the horizon, though, including one by Calypte Biomedical Corp. of California. Calypte CEO Tony Cataldo said a rapid urine test people would buy over the counter and use at home could be on the market next year.
Experts in New Jersey and at the CDC cited other benefits of rapid testing:
It can diagnose pregnant women in labor who did not get prenatal care and do not know if they are HIV positive. A study in the Journal of the American Medical Association, released today, found that 85 percent of women in labor who were approached for the test, or 4,849, agreed to be tested. Thirty-four tested positive. They and their babies were then given medication to prevent transmission of the virus to the baby. Ordinarily, nine of those babies would be expected to test positive. The last-minute medications reduced the number to three.
About 300 babies in the U.S. are born HIV positive each year. Widespread rapid testing during labor could lower that number considerably, said Mardge Cohen, co-author of the study and director of HIV research at Cook County Hospital in Chicago. She stressed that HIV testing early in pregnancy is still the best way to reduce transmission.
People are usually more willing to get HIV testing if they can get results quickly and not worry for days, said Bernard Branson, associate director of laboratory diagnostics for the CDC. "Rapid testing in the long run will help de-stigmatize HIV testing, make it more routine and more available in more places," he said.
Rapid testing will push the CDC's new initiative, Prevention For Positives, which focuses on people who are HIV positive and encourages them to take a role in stopping the spread of the disease.
For people such as Wilcher, the rapid test meant a few minutes, and not a week, of angst.
"It's better," he said. "You get tested and you don't have to wait."
Carol Ann Campbell covers medicine. She may be reached at ccampbell@starleder.com or (973) 392-4148.
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |
Calypte hat und wird keinen Rapid-Test vermarkten, demzufolge gibt es keine Zukunft für diese Firma, die Top-Leute wie Tony haben das sinkende Boot verlassen von den Top-Positionen, haben die Mios im Trockenen und warten immer nur auf dumme Aktionäre die ihr sauer verdientes Geld in den Pinkeltest investieren!
Leute wacht auf!
Es gab Zeiten da wurde alles auf Magic gesetzt und was war? NIX!
Calypte überlebt momentan nur durch MARR und durch nix anderes und die haben Optionen bzw. Verkaufskurse zu .30$ die machen sich die Taschen voll und ihr verliert euer Geld!
Nicht das mich einer falsch versteht, ich hab viel Geld mit Caly verdient aber jetzt wird nur noch abgezockt!!!!
Gruß
Jovi
PS: ich hoffe es geht deiner Frau bald besser Kade, freundschaftlicher Gruß an dich!
Der Kurs muß bei 13 $ stehen dann bin CalyEuromillionär.
Alles ist möglich
Lucky
Jeder soll seine Meinung sagen dürfen.
Aber zum jetzigen Zeitpunkt sind deine Aussagen nicht haltbar!!
1.Meinung von dir, die nicht haltbar ist ( Caly hat keinen Schnelltest)
2. Meinung von dir, die nicht haltbar ist ( Caly wird nie einen haben )
3.Meinung von dir, die nicht haltbar ist (Tony hat das Boot verlassen)
4. Meinung von dir, die nicht haltbar ist ( Abzocke)
ach ja noch was zum Thema Aids
Grüße Lucky
.N. Experts Call for Routine HIV Testing
Sat Jul 10, 1:13 PM ET Add Health - AP to My Yahoo!
By EMMA ROSS, AP Medical Writer
BANGKOK, Thailand - The current strategy of leaving it to patients to request an HIV (news - web sites) test is not working in the developing world, where 90 percent of those infected with the AIDS (news - web sites) virus have no idea they are carrying it, U.N. health experts said Saturday.
AP Photo
Yahoo! Health
Have questions about your health?
Find answers here.
The U.N. AIDS agency and World Health Organization (news - web sites) said countries where HIV is widespread and where treatment is available should test routinely — while allowing patients to opt out.
"The environment of AIDS is changing dramatically. Not only is there a globalization of the epidemic across Asia and Eastern Europe, but there is also a fundamental shift in the response, where treatment is becoming far more available," said Dr. Peter Piot, chief of UNAIDS (news - web sites).
The change in recommended police was announced ahead of Sunday's opening of the International AIDS Conference.
Patients who visit clinics "for whatever reason" and are not offered HIV tests represent missed opportunities for early diagnoses of AIDS — or even chances to discuss prevention, Piot said.
"At the moment there are millions of missed opportunities," he said.
Routine testing would come in tandem with safeguards against discrimination. Many people have avoided HIV tests fearing stigma if people know they are infected.
"We are recommending a complete package in which testing and counseling, working on stigma, social mobilization and the offer of treatment happen simultaneously," said Dr. Jim Yong Kim, director of the WHO's HIV department.
WHO has mulled routine testing for years but has not announced it as U.N. policy until now. It got behind the idea after doctors reported seeing patients they strongly suspected were HIV positive but felt constrained by the old policy requiring patients to initiate discussion about a test.
"We thought that we had to take a much stronger stand," Kim said, adding that the test must be always be consensual, confidential and accompanied by counseling.
WHO has decided that access to lifesaving therapies outweighs the need to avoid potential discrimination, Kim said.
Botswana, which has the highest HIV prevalence in the world, shifted to routine testing in January, with the proportion of patients tested for HIV jumping from 20 percent to 80 percent.
Almost everybody who comes into a health center is given a test — unless they object, said Dr. Ernest Darkoh, head of Botswana's national AIDS program.
"You realize very quickly that the whole paradigm of voluntary counseling and testing does not make sense at all in a country where you have a generalized epidemic," Darkoh said. "It just means that you reach people late. At that point they've already lost their livelihoods — at the minimum — because they are too sick to be working."
The World Health Organization aims to get 3 million sufferers in the developing world on HIV medication by the end of 2005.
Testing must be substantially ramped up to achieve that goal — with as many as a half-million people tested per day, according to the Global Business Coalition on AIDS, a network of more than 150 companies.
"A lot of things have changed in AIDS in the last 20 years, but the testing policy has largely stayed the same," coalition executive director Trevor Neilson said.
HIV testing and counseling typically are handled in a separate building from mainstream health facilities.
To tackle stigma surrounding the tests, they should be integrated with everyday health care, said South African community activist Zackie Achmat.
"What we would like to see is integration of HIV testing across the health care system, that if someone is sick with TB they are offered an HIV test, they are counseled, their confidentiality is protected."
Jovi ist der Meinung das Zocker am Werk sind und andere wie Marr,eins Caly's größter investor Geld machen. Wenn die nicht ? wer dann ?
Caly würde kein Rapid vermarkten wer dann ?
der speicheltest von Caly kommt ebenfalls, zweite hälfte von 2004 .
Wenn die kein Rapid vermarkten würden warum dann das neue logo..
Welches Unternehmen ist in diesen Regionen China,Thailand,Russland,Africa usw. sehr gut positioniert ?
Ach ja , las die mal reinschreiben.
Das sind die , die keine Caly Anteile mehr haben und auf die Große Feier den wir haben werden neidisch..
Gruß
C.O
Ich habe geschrieben sie haben die führenden Positionen verlassen, also bitte les genau, ich bin mir bewusst welche Position Tony heute hat.
Gruß Jovi
@Brokerodersowasinderrichtungderveruchtetwaszuwissen
wenn du meinst ich wäre ein schwachkopf ist das natürlich dir überlassen und ich lass mich gerne auf eine konstruktive Meinungsverschiedenheiten ein aber auf Niveau und das hast du nicht, also......cu....vielleicht wirst du ja mal dem ariva-board Ehre machen, wenn du älter wirst..
JOVI
Wenn jemand nicht haltbare Meinungen in die Welt setzt die nicht Tragbar sind, sind diese Meinungen Realitätsfremd.
Ich habe nur versucht meine Meinung zur äusern.
Ich schreibe auch nicht einfach so aus dem Bauch heraus.
Wenn Ich die Meinungen,die Äuserungen vom Kade lese, sehe ich das diese Person Recherchen darüber gemacht hat.
Entspricht der Realität..
Es gibt wiederum welche die unüberlegt ohne jegliche Kenntnisse berichten...
Gruß
C.O
@ Lucky: Na dann warten wir doch mal ab, ob das mit der Mille was wird ;-)
@ Brokersince: Welcome on board ! Hab Dich glaub ich noch gar nicht gegrüßt ?!
@Jovi: Erstmal möchte ich Dir sagen, dass ich Deine Meinung bzw. Dein Mißtrauen gegenüber Calypte teilweise nachvollziehen kann. Es ist schon viel Mist in der Vergangenheit passiert. Ich persönlich glaube trotzdem noch stark an Calys Zukunft. Bin seit nunmehr über einem Jahr investiert (also steuerfrei!). Beachte bitte, dass keineswegs alle wichtigen Personen das Boot oder die wichtigen Positionen verlassen haben ! Ich sage nur DR. RICHARD GEORGE (President and Chief Executive Officer- Calypte Director since January 2004) ! Ich sage nur ehemaliger Orasure-Chefentwickler und vorallem CDC. Das kann man nicht so einfach als Fake abtun. Der gibt seinen Namen und guten Ruf nicht so einfach her bzw. setzt diese aufs Spiel:
"Richard George, Ph.D., Dr. George has been Vice President of Governmental Affairs for the Company since January 2003 and is responsible for the development of the company's rapid urine, rapid blood and ELISA urine HIV screening products. Formerly, he acted as Senior Vice President of Research and Development, Infectious Diseases for Orasure Technologies (Nasdaq: OSUR). He was Chief of the Developmental Technology Section of the Division of HIV with the Centers for Disease Control and Prevention (CDC). Dr. George has extensive experience at the CDC where he was employed in various roles for 35 years"
Magig Johnson ist zwar noch kein Board-Member wie ursprünglich mal verkündet, allerdings ist er am letzten Weltaidstag am 01.12.2003 zusammen mit Cataldo in unzähligen großen amerikanischen Shows von morgens bis abends aufgetreten und hat Calypte beworben ! Kann man also auch nicht so einfach abtun.
Aber wie gesagt, ich kann verstehen, wenn Du mißtrauisch bist. Bist übrigens nicht der einzige, sonst wär Calypte schon längst über 2 $. Aber ich denke da kommen wir trotzdem bald wieder hin- sonst wär ich ja schließlich nicht investiert. Das Risiko ist hoch, aber die Chance um ein vielfaches höher !!! That´s my opinion.
Grüße
Kade_I
Optionen
| Boardmail an "Kade_I" |
Wertpapier: Calypte Biomedical |